Original article

Multimorbidity of four cardiometabolic and chronic pulmonary disease groups: prevalence and attributable fraction in US adults, 2007–2012

Lisa R. Staimez1*, Melissa Y. Wei2*, Min Kim1, K.M. Venkat Narayan1,3,4, Sharon H. Saydah5

1Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA; 2Division of General Medicine and Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA; 3Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA; 4Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA; 5Centers for Disease Control and Prevention, Division of Diabetes Translation, Hyattsville, MD, USA

Abstract

Background: Cardiometabolic and chronic pulmonary diseases may be associated with modifiable risk factors that can be targeted to prevent multimorbidity. Objectives: (i) Estimate the prevalence of multimorbidity across four cardiometabolic and chronic pulmonary disease groups; (ii) compare the prevalence of multimorbidity to that of one disease and no disease; and (iii) quantify population attributable fractions (PAFs) for modifiable risk factors of multimorbidity. Design: Data from adults aged 18–79 years who participated in the US National Health and Nutrition Examination Survey 2007–2012 were examined. Multimorbidity was defined as ≥2 co-occurring diseases across four common cardiometabolic and chronic pulmonary disease groups. Multivariate-adjusted PAFs for poverty, obesity, smoking, hypertension, and low high-density lipoprotein (HDL) cholesterol were estimated. Results: Among 16,676 adults, the age-standardized prevalence of multimorbidity was 9.3%. The occurrence of multimorbidity was greater with age, from 1.5% to 5.9%, 15.0% and 34.8% for adults aged 18–39, 40–54, 55–64 and 65–79 years, respectively. Multimorbidity was greatest among the poorest versus non-poorest adults and among blacks versus other races/ethnicities. Multimorbidity was also greater in adults with obesity, hypertension, and low HDL cholesterol. Risk factors with greatest PAFs were hypertension (38.8%; 95% confidence interval [CI] 29.4–47.4) and obesity (19.3%; 95% CI 10.2–28.2). Conclusions: In the USA, 9.3% of adults have multimorbidity across four chronic disease groups, with a disproportionate burden among older, black, and poor adults. Our results suggest that targeting two intermediate modifiable risk factors, hypertension and obesity, might help to reduce the prevalence of multimorbidity in US adults.

Keywords: multimorbidity, comorbidity, chronic disease prevalence, population attributable fraction, cardiovascular disease, diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease, hypertension, obesity

Introduction

Multimorbidity, commonly referred to as the co-existence of two or more chronic diseases in an individual [1–3], is associated with poor health-related quality of life, and increased healthcare utilization and cost, hospital length of stay and readmission, and mortality [4,5]. Chronic non-communicable diseases, particularly cardiometabolic [6] and chronic pulmonary diseases, are
common and fatal diseases in the USA [7]. In 2014, some of the top leading causes of death in the USA included diseases of the heart and cerebrovascular diseases, lower respiratory diseases, diabetes, and kidney diseases, including nephritis, nephrotic syndrome, and nephrosis [8]. Despite the grave consequences of these common diseases, the prevalence and quantification of risk factors using population attributable fractions (PAFs) for multimorbidity in a US-representative general adult population are not well understood.

Multimorbidity patterns, including a clustering of cardiovascular, metabolic, and psychiatric diseases, share disease pathways that have been described previously [9–11]. However, not all co-occurring diseases may be attributed to common pathophysiologic processes or the natural progression of disease. Unrelated disease patterns have been described as discordant, in which morbidities have largely unrelated pathophysiology and treatment approaches [12]. In contrast, morbidities may also have a shared pathophysiology. Diseases with a shared pathophysiology may also have related or overlapping modifiable risk factors (e.g. unhealthy diet, physical inactivity, smoking), non-modifiable risk factors (e.g. age, heredity), and intermediate risk factors (e.g. abnormal blood lipids, raised blood pressure) [13], which may additionally contribute to the overall disease risk. Modifiable risk factors are well established for many individual cardiometabolic and chronic pulmonary diseases [14], but their contribution alongside intermediate risk factors to multimorbidity in US adults aged 18–79 years has not been estimated using PAFs. Because cardiometabolic and chronic pulmonary diseases often co-occur and are caused by multiple risk factors, quantifying the contribution of risk factors to overall disease risk using PAFs will be helpful to inform strategies aimed at maximizing the prevention of these diseases. Prior studies suggest greater multimorbidity in marginalized populations, such as homeless individuals, minorities, and adults with lower socioeconomic status and educational attainment [10,15–18]. Thus, reducing healthcare disparities and targeting cost-effective interventions aimed at reducing common risk factors could have a profound impact on multimorbidity prevention.

The objectives of this study were to determine the prevalence of the multimorbidity of cardiometabolic and chronic pulmonary diseases and to quantify the preventable disease burden through the contribution of simultaneous risk factors on the multimorbidity of these diseases. We analyzed nationally representative data of community-dwelling adults aged 18–79 years, from the National Health and Nutrition Examination Survey (NHANES). Within the broader scope of cardiometabolic and chronic pulmonary diseases, we examined four common disease groups that are associated with high mortality: cardiovascular disease (CVD), diabetes mellitus, chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD).

Materials and methods

Study population

Participants included non-pregnant adults aged 18–79 years in the US NHANES 2007–2012, a nationally representative, cross-sectional survey of the resident civilian, non-institutionalized population. The survey design and analytic methods have been previously described [19–21]. Briefly, individuals participated in home interviews along with standardized anthropometric, laboratory, and pulmonary function test assessments in mobile examination centers (MECs). Participants were selected through a complex multistage-probability sampling design, and we used MEC weights in the analysis. Our analytic sample combined data from three survey periods: 2007–2008, 2009–2010, 2011–2012 to yield the final, cross-sectional sample. Overall, unweighted response rates ranged from 70% to 77% across these three survey periods [22]. All participants provided free and informed consent. The Centers for Disease Control and Prevention’s National Center for Health Statistics institutional review board approved the protocol.

Chronic disease assessment and measurement

In this analysis, we defined multimorbidity as the co-occurrence of two or more cardiometabolic and chronic pulmonary disease groups, and examined multimorbidity across the following four disease groups: CVD, diabetes mellitus, CKD, and COPD. We used self-reported physician diagnoses and additional self-reported medication use, laboratory, and procedural information as available in NHANES. Disease groups were defined as follows:

(i) CVD groups included self-reported physician-diagnosed congestive heart failure, coronary heart disease, angina, heart attack, or stroke, as used in the standardized combined questionnaire to define CVD in NHANES.

(ii) Diabetes mellitus was based on self-reported physician-diagnosed diabetes, self-reported use of diabetes medication, such as insulin or metformin, and/or a measured serum hemoglobin A1c (HbA1c) ≥6.5%. HbA1c was measured by high-performance liquid chromatography, which is standardized to the National Glycohemoglobin Standardization Program [23].

(iii) CKD was defined using the National Kidney Foundation/Kidney Disease Outcomes Quality Initiative
guidelines [24]. Glomerular filtration rate (GFR) was estimated using the CKD Epidemiology Collaboration equation [25]. Participants were classified as having CKD if they had an estimated GFR <60 mL/min/1.73 m² or an estimated GFR ≥60 mL/min/1.73 m² with albuminuria (albumin-to-creatinine ratio ≥3.4 mg/mmol [30 mg/g]) [26].

(iv) COPD was based on self-reported physician-diagnosed chronic bronchitis or emphysema, or supplemental oxygen use. We additionally included the gold standard diagnosis of COPD with pulmonary function testing based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria [27]: forced expiratory volume that can be blown out in 1 second (FEV₁) divided by forced vital capacity (FVC) less than 0.7 (i.e. FEV₁/FVC <0.7), or FEV₁/FVC ratio less than the lower limit of normal.

Assessment and measurement of risk factors

Non-modifiable risk factors included demographic factors (age [28], sex [29], race/ethnicity [30]), and upstream, contextual risk factors for disease (poverty) [31]. Age, sex, race/ethnicity, and poverty were measured by self-report. As a proxy for socioeconomic status, we included poverty, defined using the income-to-poverty ratio, a ratio of family income, and level of poverty [32]. We categorized income-to-poverty ratio into tertiles, in which ratios less than 1.5 (i.e. <150% of the federal poverty threshold) indicated the poorest individuals in the study.

For modifiable risk factors, we included the following intermediate biologic risk factors [13]: overweight/obesity [33], elevated blood pressure [34], and abnormal lipids [35,36], with their respective measures in this study including body mass index (BMI), hypertension, total cholesterol and high-density lipoprotein (HDL) cholesterol. In addition to these measures that reflect upstream factors, such as diet and physical activity, we included smoking [37] as a modifiable risk factor.

(i) Overweight/obesity: BMI was defined by clinical measures of weight and height (kg/m²) and categorized into underweight (<18.5 kg/m²), normal weight (18.5–24.9 kg/m²), overweight (25.0–29.9 kg/m²), and obese (≥30.0 kg/m²) [38]. Underweight estimates were not shown due to small sample sizes (n=90 participants who met inclusion criteria) as suggested by NHANES recommendations for reliable estimates [21].

(ii) Hypertension was identified by self-reported physician-diagnosed hypertension and the standard clinical diagnosis of hypertension available through systolic and diastolic blood pressure readings, which were each measured up to four times and averaged. Hypertension was defined as mean systolic blood pressure ≥140 mmHg or mean diastolic blood pressure ≥90 mmHg.

(iii) Dyslipidemia: high total cholesterol and low HDL cholesterol were based on standard definitions of laboratory measures (total cholesterol ≥200 mg/dL or HDL cholesterol <40 mg/dL for men and <50 mg/dL for women).

(iv) Smoking was based on self-report using both the lifetime smoking variable (ever smoked at least 100 cigarettes) in combination with current smoking status and categorized as current, former, or never smoker.

Statistical analysis

Between 2007 and 2012, 29,353 individuals participated in NHANES. Among this pool, 12,676 participants (43%, unweighted sample) were excluded based on age (<18 years or >79 years) or current pregnancy, with 16,677 participants remaining in the sample. We used a complex sampling design in all analyses. Prevalence estimates of the four disease group outcomes (CVD, diabetes, CKD, and COPD) were stratified by non-modifiable and modifiable risk factors including age, sex, race/ethnicity, poverty, BMI, smoking status, hypertension, total cholesterol, and HDL cholesterol. Chi-square tests were used to compare those who developed disease (e.g. CVD) with those who did not develop disease across categories of risk factors. All significance levels were set at p<0.05.

We conducted a multivariate, multiple imputation procedure to impute values for missing disease outcomes. Missing data were greatest for COPD (21.3% of the sample) compared with the other three diseases (CKD 10.6%, CVD 5.3%, and diabetes 0%), similar to existing reports of missing data in NHANES [39]. A weighted sequential hot-deck imputation was performed in SUDAAN [40]. We replaced missing values by taking values from observations with no missing values, with a single donor providing values for the missing outcome of a single recipient. The sample size for the imputed dataset was 16,676, which was used to estimate the prevalence of co-occurring disease combinations in multimorbidity. Results were age-standardized [41] to the 2010 US census population using the age categories 18–39, 40–54, 55–64, and 65–79 years.

Multivariate regression analyses were used to calculate risk ratios (RRs), PAF estimates for modifiable risk factors, and the 95% confidence intervals (CIs) of the PAF using predicted marginals obtained from the RLOGIST (logistic regression) procedure in SUDAAN.
Among adults with diabetes, over half had cardiometabolic co-occurring diabetes, CKD, and/or COPD. The prevalence of the risk factor among those with multimorbidity. The adjusted PAF (PAF_adj) was calculated as follows: \((\text{number exposed cases/total cases}) \times (\text{adjusted RR} - 1)/\text{adjusted RR}\) [36] and using Bonferroni correction for 95% CI estimation [42] (see Supplementary Methods). Multivariate regression excluded participants for missing risk factor data, yielding regression estimates based on 13,331 participants, weighted to represent 180,807,323 US adults. Interactions between risk factors could not be assessed due to the limited sample size. To examine potential bias from missing outcome data, we compared multimorbidity prevalence estimates and PAFs from imputed data, as provided in the results section, with results from non-imputed data (Supplementary Tables 1 and 2), and bias was not detected. All analyses were based on SAS version 9.3 and SUDAAN version 11.0.

**Results**

In a nationally representative sample of non-institutionalized US adults, 17.3% had COPD, 11.6% had CKD, 10.6% had diabetes, and 6.9% had CVD (Table 1). For any disease, the prevalence estimates were significantly greater across older age categories \((p<0.001)\). While the prevalence of any of the four disease groups was greatest in adults aged 65–79 years (CVD 23.8%, diabetes 25.9%, CKD 33.9%, COPD 35.3%), younger and middle-aged adults aged 18–39 years also developed chronic diseases with a similar pattern to that of older adults (CVD 1.2%, diabetes 2.6%, CKD 5.9%, COPD 10.4%). Across race/ethnicity categories for the total sample, non-Hispanic blacks had the greatest prevalence of CVD (8.3%), diabetes (16.3%), and CKD (15.0%) compared with non-Hispanic whites, Hispanics, and those who were classified as other race or multiracial (all \(p<0.001\)). The prevalence of each disease group, except COPD, was significantly greater in individuals with a lower income-to-poverty ratio \((p<0.0001\) across tertiles of income-to-poverty ratios for those with CVD, diabetes, and CKD) (Table 1).

The prevalence estimates of co-occurring disease clusters were assessed (Table 2). The three most common dyads of diseases were (i) diabetes and CKD, (ii) CKD and COPD, and (iii) CVD and COPD. Among adults with CVD, over two-thirds had multimorbidity from co-occurring diabetes, CKD, and/or COPD. Among adults with diabetes, over half had cardiometabolic or chronic respiratory multimorbidity, similar to the proportion of adults with CKD with these co-morbidities. Among adults with COPD, nearly one-third had multimorbidity from co-occurring CVD, diabetes, and/or CKD. The prevalence estimates of specific disease combinations are provided in Figure 1, illustrating the 11 different combinations of multimorbidity in this study. The occurrence of multimorbidity was greater with age, from 1.5\% (95\% CI 1.2–1.9) for adults aged 18–39 years, to 5.9\% (95\% CI 5.0–6.9) for those aged 40–54 years, 15.0\% (96\% CI 13.2–16.9) for those aged 55–64 years and 34.8\% (95\% CI 32.4–37.2) for those aged 65–79 years.

Table 3 provides the age-standardized prevalence levels of zero, one, and two disease-group combinations for various demographic factors and modifiable risk factors. The age-standardized prevalence of multimorbidity of two or more cardiometabolic and chronic pulmonary disease groups among US adults was 9.3\% (95\% CI 8.8–9.9) (Table 3), using imputed data (see Supplementary Table 1 for results from original, non-imputed data). The distribution of age-standardized multimorbidity across demographic variables differed when compared with the distribution of demographic factors related to having only one chronic disease. Specifically, age-standardized multimorbidity was greatest among non-Hispanic blacks compared with non-Hispanic whites and other race/ethnicities. However, disparities between non-Hispanic blacks and non-Hispanic whites were not statistically significant for the outcome of one chronic condition. Multimorbidity was greatest among those in the lowest tertile of the income-to-poverty ratio compared with the middle or highest tertiles. Multimorbidity was greater among men compared with women.

For modifiable risk factors, age-standardized multimorbidity was highest in obese adults compared with overweight and normal BMI adults (Table 3). There was no significant difference in the prevalence of multimorbidity between adults with normal BMI versus overweight adults. The prevalence of multimorbidity was also greater in current smokers versus former and never smokers, in those with hypertension versus without hypertension, and in those with low HDL cholesterol versus normal HDL cholesterol.

Table 4 includes the adjusted RRs, PAF_adj, and 95\% CIs of RRs and PAFs for modifiable risk factors, using imputed data (See Supplementary Table 2 for results from original non-imputed data). Across all measured modifiable risk factors, hypertension was the greatest contributor of multimorbidity (PAF_adj 38.8\%; 95\% CI 29.4–47.4). Other important covariates with high PAF_adj for multimorbidity were obesity (19.3\%; 95\% CI 10.2–28.2), current smoking (10.7\%; 95\% CI 6.6–15.1), former smoking (8.4\%; 95\% CI 2.5–14.4), and low HDL
Table 1  Prevalence of cardiometabolic and chronic pulmonary disease groups among US adults aged 18–79 years in the National Health and Nutrition Examination Survey, 2007–2012.

| Characteristic                           | Cardiovascular disease (N=15,789) | Diabetes (N=16,677) | Chronic kidney disease (N=15,384) | Chronic obstructive pulmonary disease (N=13,544) |
|------------------------------------------|-----------------------------------|--------------------|-----------------------------------|-----------------------------------------------|
|                                          | n                                 | % (95% CI)         | n                                 | % (95% CI)                                  | n                                 | % (95% CI) |
| Total with disease                       | 1,469                             | 6.9 (6.3–7.5)      | 2,463                             | 10.6 (9.8–11.4)                             | 2,483                             | 11.6 (10.9–12.4) |
| Age, years                               |                                   |                    |                                   |                                               |                                   |            |
| 18–39                                    | 85                                | 1.2 (0.9–1.5)      | 207                               | 2.6 (2.1–3.1)                               | 417                               | 5.9 (5.3–6.6) |
| 40–54                                    | 271                               | 5.0 (4.3–5.8)      | 605                               | 10.5 (9.2–12.0)                             | 460                               | 8.2 (7.0–9.5) |
| 55–64                                    | 379                               | 11.0 (9.5–12.6)    | 726                               | 18.1 (15.7–20.8)                            | 516                               | 14.2 (12.1–16.5) |
| 65–79                                    | 734                               | 23.8 (21.6–26.1)   | 925                               | 25.9 (23.4–28.6)                            | 1,090                             | 33.9 (32.3–35.5) |
| p <0.0001                                |                                   |                    |                                   |                                               |                                   |            |
| Sex                                      | Male                              | 832                | 7.9 (7.1–8.7)                     | 1,255                                         | 11.0 (10.1–12.0)                   | 1,166                             | 10.2 (9.3–11.3) |
|                                          | Female                            | 636                | 5.9 (5.3–6.7)                     | 1,208                                         | 10.1 (9.2–11.2)                    | 1,317                             | 13.0 (12.1–13.9) |
| p <0.0001                                |                                   |                    |                                   |                                               |                                   |            |
| Race                                      | White/non-Hispanic                | 703                | 7.2 (6.5–8.1)                     | 794                                           | 9.1 (8.1–10.2)                     | 995                               | 11.2 (10.4–12.1) |
|                                          | Black/non-Hispanic                | 384                | 8.3 (7.4–9.3)                     | 740                                           | 16.3 (14.8–17.9)                   | 684                               | 15.0 (13.8–16.3) |
|                                          | Hispanic                          | 295                | 4.5 (3.8–5.4)                     | 740                                           | 11.8 (10.6–13.2)                   | 623                               | 11.3 (10.0–12.7) |
|                                          | Other race/multiracial             | 86                 | 6.3 (4.6–8.4)                     | 189                                           | 12.8 (10.0–16.1)                   | 180                               | 10.4 (8.1–13.2) |
| p <0.0001                                |                                   |                    |                                   |                                               |                                   |            |
| Body mass index, kg/m²                   |                                   |                    |                                   |                                               |                                   |            |
| <18.5 (underweight)                      | 20                               | 4.7 (2.7–8.0)      | 4                                 | 0.6 (0.2–1.7)                               | 56                                | 14.6 (10.3–20.3) |
| 18.5 to <25 (normal)                     | 261                              | 4.1 (3.5–4.9)      | 270                               | 3.6 (3.0–4.4)                               | 532                               | 9.5 (8.5–10.6) |
| 25 to <30 (overweight)                   | 419                              | 6.0 (5.2–6.9)      | 627                               | 7.2 (6.5–8.0)                               | 678                               | 9.3 (8.3–10.5) |
| ≥30 (obese)                              | 723                              | 9.9 (8.9–10.9)     | 1,500                             | 20.0 (18.3–21.7)                             | 1,151                             | 15.1 (13.8–16.5) |
| p <0.0001                                |                                   |                    |                                   |                                               |                                   |            |
| Smoking status                           |                                   |                    |                                   |                                               |                                   |            |
| Current smoker                           | 385                              | 8.2 (7.1–9.5)      | 463                               | 9.6 (8.5–10.8)                              | 496                               | 10.8 (9.6–12.1) |
| Former smoker                            | 550                              | 11.6 (10.3–13.1)   | 793                               | 15.2 (13.5–17.0)                             | 730                               | 15.0 (13.3–16.9) |
| Never smoker                             | 529                              | 4.8 (4.2–5.4)      | 1,193                             | 9.6 (8.7–10.6)                              | 1,173                             | 10.6 (9.8–11.5) |
| p <0.0001                                |                                   |                    |                                   |                                               |                                   |            |
| Hypertension                             |                                   |                    |                                   |                                               |                                   |            |
| Yes (Stages 1 & 2)                       | 1,159                            | 15.3 (14.1–16.5)   | 1,790                             | 22.0 (20.3–23.8)                             | 1,692                             | 21.2 (20.0–22.5) |
| No (normal/pre-hypertension)             | 310                              | 2.7 (2.3–3.1)      | 673                               | 4.8 (4.3–5.4)                               | 791                               | 6.8 (6.0–7.6) |
| p <0.0001                                |                                   |                    |                                   |                                               |                                   |            |
| Total cholesterol                       |                                   |                    |                                   |                                               |                                   |            |
| High (>200 mg/dL)                        | 1,042                            | 9.1 (8.5–9.9)      | 1,762                             | 13.9 (12.8–15.1)                             | 1,626                             | 13.9 (12.9–15.0) |
| Normal (<200 mg/dL)                      | 412                              | 4.2 (3.6–5.0)      | 689                               | 6.7 (6.0–7.4)                               | 834                               | 8.9 (8.1–9.8) |
| p <0.0001                                |                                   |                    |                                   |                                               |                                   |            |

© 2017 The Authors Published by Swiss Medical Press GmbH | www.swissmedicalpress.com Journal of Comorbidity 2017;7(1):22–32
cholesterol (13.2%; 95% CI 7.9–18.8). Total cholesterol and being overweight did not have a statistically significant PAFadj for multimorbidity.

Discussion

We present prevalence and PAF estimates for the multimorbidity of four highly prevalent cardiometabolic and chronic pulmonary disease groups associated with high mortality in a nationally representative sample of non-institutionalized US adults aged 18–79 years. Nearly 10% of adults had two or more co-occurring conditions, with the most prevalent three disease dyads being (i) diabetes and CKD, (ii) CKD and COPD, and (iii) CVD and COPD. Men, non-Hispanic black adults, and adults with the lowest income-to-poverty ratio had a greater burden of multimorbidity compared with women, non-Hispanic white adults, and adults with higher income-to-poverty ratios, respectively, suggesting persistent healthcare disparities. Among all adults, multimorbidity was most attributable to two intermediate biologic risk factors, hypertension and obesity, which are often considered as end conditions in other studies, but are both preventable and treatable, and thus considered in this study as modifiable risk factors for which one may quantify their contribution to disease burden. Reducing hypertension and obesity may effectively reduce the burden of multimorbidity in the USA. Our

Table 2 Age-standardized prevalence of cardiometabolic and chronic pulmonary disease combinations in the National Health and Nutrition Examination Survey, 2007–2012, without missing outcomes or exposures, N=16,676 (weighted sample N=214,841,629).

| Chronic disease(s) | n   | %   | 95% CI       |
|--------------------|-----|-----|--------------|
| No chronic disease | 10,265 | 66.1 | 65.2–67.1    |
| One chronic disease| 4,297  | 24.5 | 23.7–25.4    |
| CVD                | 472   | 2.4  | 2.1–2.7      |
| Diabetes           | 1,055 | 6.4  | 6.0–6.8      |
| CKD                | 1,035 | 6.2  | 5.8–6.6      |
| COPD               | 1,736 | 11.1 | 10.8–11.5    |
| Two chronic diseases| 1,492 | 6.8  | 6.4–7.3      |
| CVD, diabetes      | 198   | 0.8  | 0.6–1.1      |
| CVD, CKD           | 135   | 0.6  | 0.5–0.7      |
| CVD, COPD          | 176   | 1.1  | 0.9–1.4      |
| Diabetes, CKD      | 206   | 1.2  | 0.9–1.5      |
| Diabetes, COPD     | 302   | 1.8  | 1.4–2.2      |
| Three chronic diseases| 525  | 3.2  | 2.8–3.6      |
| CVD, diabetes, CKD | 213   | 0.8  | 0.6–1.0      |
| CVD, diabetes, COPD| 85    | 0.4  | 0.3–0.5      |
| CVD, CKD, COPD     | 93    | 0.4  | 0.3–0.6      |
| Diabetes, CKD, COPD| 135   | 0.5  | 0.4–0.7      |
| Four chronic diseases| 97   | 0.4  | 0.3–0.6      |

CI, confidence interval; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease.
PAF estimates suggest that eliminating hypertension, while holding other risk factors constant, may translate to a one-third reduction in multimorbidity.

We observed differences in risk factors among adults with multimorbidity versus those with no diseases that were not apparent when comparing adults with one disease versus none, suggesting that multimorbidity may confer a distinctive risk phenotype. The accumulation and/or combination of risk factors may reach a threshold effect after which individuals have increased vulnerability and susceptibility to acquiring more diseases, or alternatively, the resulting progression in multimorbidity may reflect failures in self-management or multispecialty-based management with challenges such as medication adherence and therapeutic competition.

Studies on the prevalence of multimorbidity are highly sensitive to the methods used to define multimorbidity, such as a disease count of two or more coexisting conditions, the inventory of available diseases and conditions, and the population of interest. In our sample of nationally representative US adults aged 18–79 years, disease group prevalences for CVD, diabetes, CKD, and COPD were similar to those reported in prior studies using data from NHANES [43–47]. Our multimorbidity prevalence estimates are further consistent with studies that examined dyads of diseases and comorbidity combinations, such as CVD and CKD, CVD and diabetes, and diabetes and CKD [45,46], and, similar to other studies, are limited to a few select, but highly prevalent, diseases. Future studies may examine disease combinations and interactions, but will require complex modeling for potential higher-order, multiplicative interactions.

Few studies have examined modifiable risk factors, including intermediate risk factors [11], or quantified their contribution to multimorbidity using adjusted PAFs in nationally representative US adults aged 18–79 years. Van Baal et al. examined the prevalence of the co-occurrence of four of the most highly prevalent chronic diseases (diabetes, myocardial infarction, stroke, and cancer) in the Dutch population [48]. The authors demonstrated that disease co-occurrence occurred more frequently than that expected by the individual diseases alone. The authors postulated that co-occurring diseases share common pathways, such as high blood pressure, cholesterol, smoking, and obesity. The co-occurring diseases increased with age, although the authors did not examine other risk factors [48]. In our study, we reported a similar increasing prevalence of multimorbidity with age and other risk factors using a comparable group of diseases, except that we included CKD and COPD and not cancer.

One cross-sectional study by Fortin et al. [49] examined the association between lifestyle factors and the likelihood of multimorbidity. Multimorbidity was
defined as a simple count of three or more of 14 potential chronic conditions, among them CVD, diabetes, and COPD. The odds of multimorbidity were greatest for past or current smoking in men, and for non-normal BMI (either underweight or overweight/obesity) in both sexes. However, the odds of multimorbidity did not differ significantly based on socioeconomic status, education, alcohol use, or low fruit and vegetable consumption. In our study, we demonstrated high PAFs for smoking and obesity, similar to the findings of Fortin et al. [49]. However, we additionally reported a greater burden of multimorbidity for non-Hispanic black adults and those with a low income-to-poverty ratio, in contrast to the findings of Fortin et al. [49]. The differences in socioeconomic status in the two studies might potentially be explained by the categorization of socioeconomic class. While our study did not examine the association between nutrition and multimorbidity, one study reported that greater consumption of vegetables, fruits, and grains was linked to a lower risk of multimorbidity, based on the evaluation of 11 diseases over 5 years [50]. However, a second study reported no association between low fruit and vegetable consumption and the presence of multimorbidity [49].

We note limitations to our study. First, our sample population focused on community-dwelling adults and did not include nursing home residents and adults 80 years and older (who may have a higher prevalence of cognitive impairment and less reliable self-report), which may underestimate disease prevalence. Second, our prevalence of CVD using physician-diagnosed CVD may be subject to recall bias, under-reporting, and under-diagnosis, as confirmatory catheterization and imaging reports are not collected in NHANES. However, our prevalence estimate is similar to prior estimates in NHANES [44]. Third, for all analyses, we used and presented results utilizing multiple imputation due to some missing data to determine COPD or CKD, although we report original, non-imputed values.

Table 3 Age-standardized prevalence of common cardiometabolic and chronic pulmonary diseases among US adults aged 18–79 years in the National Health and Nutrition Examination Survey, 2007–2012.

| No disease | One disease | Two or more diseases |
|------------|-------------|----------------------|
| n          | %           | 95% CI               | n          | %           | 95% CI               | n          | %           | 95% CI               |
| Total individuals | 10,265 | 66.1 | 65.2–67.1 | 4,297 | 24.3 | 23.7–25.4 | 2,114 | 9.3 | 8.8–9.9 |
| Sex | | | | | | | | | |
| Male | 4,995 | 64.3 | 62.7–65.9 | 2,124 | 25.0 | 23.7–26.3 | 1,174 | 10.7 | 9.9–11.6 |
| Female | 5,270 | 67.7 | 66.2–69.1 | 2,173 | 24.2 | 22.9–25.6 | 940 | 8.1 | 7.3–9.0 |
| Race/ethnicity | | | | | | | | | |
| White/non-Hispanic | 4,173 | 67.3 | 66.0–68.5 | 1,835 | 24.2 | 23.1–25.4 | 921 | 8.5 | 7.8–9.3 |
| Black/non-Hispanic | 2,144 | 60.6 | 58.6–62.5 | 1,026 | 26.2 | 24.4–28.1 | 585 | 13.2 | 12.1–14.4 |
| Hispanic | 2,962 | 66.2 | 64.3–68.0 | 1,083 | 23.8 | 22.5–25.2 | 473 | 10.0 | 8.9–11.3 |
| Other race/multiracial | 987 | 64.0 | 59.1–68.5 | 353 | 25.6 | 21.9–29.6 | 134 | 10.5 | 8.0–13.5 |
| Income-to-poverty ratio | | | | | | | | | |
| 0.00 to <1.50 | 3,608 | 59.1 | 57.7–60.5 | 1,654 | 27.1 | 25.8–28.4 | 905 | 13.8 | 12.7–15.0 |
| 1.50 to <3.50 | 2,738 | 66.2 | 64.1–68.3 | 1,156 | 24.4 | 22.6–26.4 | 603 | 9.3 | 8.4–10.3 |
| ≥3.50 | 2,985 | 69.9 | 66.9–71.8 | 1,100 | 23.1 | 21.2–25.0 | 407 | 7.1 | 6.4–7.9 |
| Body mass index, kg/m² | | | | | | | | | |
| 18.5 to <25 | 3,194 | 68.0 | 66.3–69.6 | 1,139 | 25.4 | 23.8–27.0 | 353 | 6.6 | 5.7–7.7 |
| 25 to <30 | 3,477 | 70.0 | 68.8–71.2 | 1,296 | 22.7 | 21.6–23.9 | 600 | 7.3 | 6.6–8.0 |
| ≥30 | 3,307 | 61.7 | 59.9–63.5 | 1,715 | 25.4 | 23.9–26.9 | 1,072 | 12.9 | 11.8–14.1 |
| Smoking status | | | | | | | | | |
| Current smoker | 2,021 | 54.9 | 53.0–56.8 | 1,082 | 30.7 | 28.6–33.0 | 495 | 14.4 | 12.7–16.2 |
| Former smoker | 1,766 | 64.5 | 62.0–66.9 | 1,087 | 25.8 | 23.5–28.2 | 762 | 9.7 | 8.6–10.9 |
| Never smoker | 5,745 | 71.6 | 70.3–72.8 | 1,979 | 21.1 | 20.0–22.3 | 842 | 7.3 | 6.6–8.1 |
| Hypertension | | | | | | | | | |
| Yes (stages 1 & 2) | 2,604 | 57.4 | 55.6–59.2 | 2,103 | 28.7 | 27.2–30.3 | 1,651 | 13.9 | 13.0–14.9 |
| No (normal/pre-hypertension) | 7,661 | 71.4 | 69.9–72.8 | 2,195 | 23.1 | 21.8–24.3 | 463 | 5.5 | 4.8–6.4 |
| Total cholesterol | | | | | | | | | |
| High (≥200 mg/dL) | 4,935 | 65.2 | 63.8–66.5 | 2,542 | 24.9 | 23.6–26.2 | 1,524 | 10.0 | 9.3–10.7 |
| Normal (<200 mg/dL) | 5,102 | 66.5 | 65.0–68.0 | 1,691 | 24.8 | 23.1–26.5 | 574 | 8.7 | 7.7–9.8 |
| HDL cholesterol | | | | | | | | | |
| Low | 2,960 | 61.1 | 59.1–63.0 | 1,359 | 25.6 | 24.1–27.2 | 811 | 13.4 | 12.4–14.4 |
| Normal | 6,649 | 68.6 | 67.5–69.6 | 2,629 | 23.9 | 22.9–24.9 | 1,162 | 7.6 | 7.0–8.1 |

Age-standardized to 2010 US census population. n represents unweighted counts. Unweighted sample size N=16,676. Weighted sample size N=214,841,629. Percentages and 95% confidence intervals (CI) are based on weighted counts. HDL, high-density lipoprotein.
data indicating similar results (See supplementary Tables 1 and 2) suggesting lack of bias from missing data. Finally, our study was cross-sectional and cannot be used to ascertain the temporality of risk factors or causality of these risk factors with multimorbidity. Reverse causation for adults with multimorbidity could modestly inflate the modifiable risk factors measured in this study. Future studies will benefit from longitudinal study designs and a more expansive inventory of risk factors.

Multimorbidity is a common but modifiable phenomenon. Our results suggest that targeting two intermediate risk factors, hypertension and obesity, might prevent over half of multimorbidity in US adults aged 18–79 years. Additionally, to reduce the widening of health disparities, public health programs and healthcare policies should target marginalized populations disproportionately burdened by multimorbidity, including older adults, non-Hispanic blacks, and adults with a low income-to-poverty ratio.

Conflicts of interest

No financial, consultant, institutional, or other relationships were reported by the authors of this paper. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Funding

None.

References

1 Almirall J, Fortin M. The coexistence of terms to describe the presence of multiple concurrent diseases. J Comorbidity 2013;3(1):4–9. View Item
2 Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 1970;23(7):455–68. View Item
3 Van den Akker M, Buntinx F, Knoottnerus JA. Comorbidity or multimorbidity: what’s in a name? A review of literature. Eur J Gen Pract 1996;2(2):65–70. View Item
4 Nobrega TC, Jalul O, Machado AN, Paschoal SM, Jacob Filho W. Quality of life and multimorbidity of elderly outpatients. Clinics (Sao Paulo) 2009;64(1):45–50. View Item
5 Anderson G. Chronic care: making the case for ongoing care: Robert Wood Johnson Foundation; 2010. Available from: rwjf.org/en/research-publications/find-rwjf-research/2010/01/chronic-care. html [Last accessed Feb 7, 2017].
6 Castro JP, El-Atat FA, McFarlane SI, Aneja A, Sowers JR. Cardiometabolic syndrome: pathophysiology and treatment. Curr Hypertens Rep 2003;5(8):393–401. View Item
7 National Center for Health Statistics. Leading causes of death and numbers of deaths, by sex, race, and Hispanic origin: United States, 1980 and 2014 (Table 19). Washington, DC: National Center for Health Statistics, 2015. Available from: http://www.cdc.gov/nchs/data/hus/hus15.pdf#019 [Last accessed Feb 7, 2017].

Table 4 Population attributable fractions (PAFs) of modifiable risk factors for multimorbidity in US adults aged 18–79 years in the National Health and Nutrition Examination Survey, Age-Standardized, 2007–2012.

| Modifiable risk factor | Risk ratio (RR) of multimorbidity | PAFadj | 95% CI | PAF% | 95% CI |
|------------------------|---------------------------------|--------|-------|------|-------|
| Body mass index, kg/m² |                                 |        |       |      |       |
| 18.5 to <25 Reference |                                 |        |       |      |       |
| 25 to <30 0.96        | 0.80–1.16                       | -1.05  | -6.91–4.33 |
| ≥30 1.55              | 1.29–1.86                       | 19.26  | 10.15–28.08 |
| Smoking status |                                 |        |       |      |       |
| Current smoker 1.75   | 1.47–2.07                       | 10.68  | 6.62–15.08 |
| Former smoker 1.29    | 1.10–1.51                       | 8.40   | 2.45–14.38 |
| Never smoker Reference |                                 |        |       |      |       |
| Hypertension |                                 |        |       |      |       |
| Yes (Stages 1 & 2) 2.10 | 1.76–2.49                       | 38.84  | 29.43–47.36 |
| No (normal/pre-hypertension) Reference |                                 |        |       |      |       |
| Total cholesterol |                                 |        |       |      |       |
| High (≥200 mg/dL) 1.18 | 1.02–1.36                       | 11.30  | 0.13–21.76 |
| Normal (<200 mg/dL) Reference |                                 |        |       |      |       |
| HDL cholesterol |                                 |        |       |      |       |
| Low 1.45 | 1.28–1.65                       | 13.19  | 7.85–18.81 |
| Normal Reference |                                 |        |       |      |       |

Analyses were age-standardized to 2010 US census population. Unweighted total sample size N=13,331. Weighted total sample size N=180,807,323. Estimates were adjusted for risk factors listed within the table, as well as sex, race/ethnicity, and income-to-poverty ratio. CI, confidence interval; HDL, high-density lipoprotein; PAFadj, adjusted PAF.
Multimorbidity prevalence and prevention

8 GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2013;385(9963):1–264. View Item

9 Schäfer I, von Lettner EC, Schön G, Koller D, Hansen H, Kolonko T, et al. Multimorbidity patterns in the elderly: a new approach of disease clustering identifies complex interrelations between chronic conditions. PLoS ONE 2010;5(12):e15941. View Item

10 Barnett K, Mercer S, Norbury M, Watt G, Wkye S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross sectional study. Lancet 2012;380(9836):37–43. View Item

11 Violan C, Fogueu-Boreu Q, Flores-Mateo G, Salisbury C, Blom J, Freitag M, et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS ONE 2014;9(7):e102149. View Item

12 Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care 2006;29(3):728–31. View Item

13 World Health Organization. Preventing chronic disease: a vital investment. Geneva: World Health Organization, 2016. Available from: http://www.who.int/chp/chronic_disease_report/presentation/en/ [Last accessed Feb 7, 2017].

14 World Health Organization. Preventing chronic disease: a vital investment. Part Two. The urgent need for action. Chapter One. Chronic diseases: causes and health impact. Geneva: World Health Organization, 2005. Available from: http://www.who.int/chp/chronic_disease_report/part2_ch1/en/index1.html [Last accessed Feb 7, 2017].

15 Brett T, Arnold-Reed DE, Troeung L, Bulsara MK, Williams A, O'Brien R, Wyke S, Guthrie B, Watt G, Mercer SW. The 'everday work' of living with multimorbidity in socioeconomically deprived areas of Scotland. J Comorbidity 2014;4(1):1–10. View Item

16 Mathur R, Hull SA, Badrick E, Robson J. Cardiovascular multimorbidity: the effect of ethnicity on prevalence and risk factor management. Br J Gen Pract 2011;61(586):e262–70. View Item

17 Nagel G, Peter B, Braig S, Hermann S, Rohrmann S, Limesen J. The impact of education on risk factors and the occurrence of multimorbidity in the EPIC-Heidelberg cohort. BMC Public Health 2008;8:384. View Item

18 Curtin LR, Mohadjer LK, Ohmann SM, Kruzon-Moran D, Mirel LB, Carroll MD et al. National Health and Nutrition Examination Survey: sample design, 2007–2010. Vital Health Stat 2 2013;(160):1–32.

19 Mirel LB, Mohadjer LK, Ohmann SM, Clark J, Burt VL, Johnson CL, et al. National Health and Nutrition Examination Survey: estimation procedures, 2007–2010. Vital Health Stat 2 2013;(159):1–17.

20 Johnson CL, Paulose-Ram R, Ogden CL, Carroll MD, Kruzon-Moran D, Ohmann SM et al. National Health and Nutrition Examination Survey: analytic guidelines, 1999–2010. Vital Health Stat 2 2013;(161):1–24.

21 National Center for Health Statistics. National Health and Nutrition Examination Survey: Analytic Guidelines, 2011–2012. Washington, DC: National Center for Health Statistics, 2013. Available from: http://www.cdc.gov/nchs/data/nhanes/analytic_guidelines_11_12.pdf [Last accessed Feb 7, 2017].

22 Little RR. Glycated hemoglobin standardization—National Glycohemoglobin Standardization Program (NGSP) perspective. Clin Chem Lab Med 2003;41(9):1191–8. View Item

23 Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1.

24 Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604–12. View Item

25 Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139(2):137–47. View Item

26 Pawels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, Committee GS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary Ann J Respir Crit Care Med 2001;163(6):1256–76. View Item

27 Ayres BN, Shigenaga MK, Hagen TM. Oxidants antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993;90(17):7915–22.

28 Chen Y, Brethaupt K, Muhajarine N. Occurrence of chronic obstructive pulmonary disease among Canadians and sex-related risk factors. J Clin Epidemiol 2000;53(7):755–61. View Item

29 Kurian AK, Cardarelli KM. Racial and ethnic differences in cardiovascular disease risk factors: a systematic review. Ethn Dis 2007;17:143–52.

30 Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: overcoming impediments to prevention and control. JAMA 2004;291(21):2616–22. View Item

31 National Center for Health Statistics. National Health and Nutrition Examination Survey: 2011–2012 Data Documentation, Codebook, and Frequencies. Available from: https://www.cdc.gov/Nchs/NHANES/2011-2012/DEMO_G.htm [Last accessed Feb 19, 2017].

32 Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales BS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289(1):76–9. View Item

33 Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–47. View Item

34 Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–47. View Item

35 Patel SA, Winkel M, Ali MK, Narayan KMV, Mehta NK. Cardiovascular mortality associated with leading risk factors. Ann Intern Med 2015;163(4):245–53. View Item

36 Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalkoudh S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256(2):2835–8. View Item

37 Centers for Disease Control and Prevention (CDC). Smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 2000–2004. MMWR. Morb Mortal Wkly Rep 2008;57(45):1226–8.

38 Centers for Disease Control and Prevention. About Adult BMI. Available from: https://www.cdc.gov/healthyliving/assessing/bmi/adult_bmi/ [Last accessed Feb 7, 2017].

39 Doney B, Hnizdo E, Dillon CF, Paulose-Ram R, Tilet T, Wolz M, et al. Prevalence of airflow obstruction in U.S. adults aged 40–79 years: NHANES data 1988–1994 and 2007–2010. COPD 2015;12(4):355–65. View Item

40 Ault K. Paper SD-12. Multiple imputation for ordinal variables: a comparison of SUDAAN PROC IMPUTE and SAS® PROC MI. Available from: http://analytics.ncsu.edu/sesug/2012/SD-12.pdf [Last accessed Feb 7, 2017].

41 National Center for Health Statistics. National Health and Nutrition Examination Survey: Age Standardization and Populations Counts. Available from: https://www.cdc.gov/nchs/tutorials/NHANES/NHANESAnalyses/AgeStandardization/age_standardization_intro.htm [Last accessed Feb 20, 2017].
42. Natarajan S, Lipsitz SR, Rimm E. A simple method of determining confidence intervals for population attributable risk from complex surveys. Stat Med 2007;26(17):3229–39.

43. Goldfarb-Rumyantzev A, Gautam S, Brown RS. Practical prediction model for the risk of 2-year mortality of individuals in the general population. J Investig Med 2016;64(4):848–53.

44. Alshaarawy O, Elbaz HA, Andrew ME. The association of urinary polycyclic aromatic hydrocarbon biomarkers and cardiovascular disease in the US population. Environ Int 2016;89-90:174–8.

45. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988–2012. JAMA 2015;314(10):1021–9.

46. Patel N, Golzy M, Namani N, Nader ND, Carter RL, Lohr JW, et al. Prevalence of various comorbidities among veterans with chronic kidney disease and its comparison with other datasets. Ren Fail 2016;38(2):204–8.

47. Ford ES, Mannino DM, Wheaton AG, Giles WH, Presley-Cantrell L, Croft JB. Trends in the prevalence of obstructive and restrictive lung function among adults in the United States: findings from the National Health and Nutrition Examination surveys from 1988–1994 to 2007–2010. Chest 2013;143(5):1395–406.

48. Van Baal PH, Engelfriet PM, Boshuizen HC, Van de Kasteele J, Schellevis FG, Hoogenveen RT. Co-occurrence of diabetes, myocardial infarction, stroke, and cancer: quantifying age patterns in the Dutch population using health survey data. Popul Health Metr 2011;9(1):51.

49. Fortin M, Haggerty J, Almirall J, Bouhali T, Sasseville M, Lemieux M. Lifestyle factors and multimorbidity: a cross sectional study. BMC Public Health 2014;14:686.

50. Ruel G, Shi Z, Zhen S, Zuo H, Kroger E, Sirois C, et al. Association between nutrition and the evolution of multimorbidity: the importance of fruits and vegetables and whole grain products. Clin Nutr 2013;33(3):53–20.